CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹987 Cr | ₹936 Cr | ₹634 Cr | ₹567 Cr | ₹743 Cr |
What is the latest Contingent Liabilities ratio of CIPLA ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹987 Cr |
| Mar2025 | ₹936 Cr |
| Mar2024 | ₹634 Cr |
| Mar2023 | ₹567 Cr |
| Mar2022 | ₹743 Cr |
How is Contingent Liabilities of CIPLA Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹987 Cr | 5.48 | |
| Mar2025 | ₹936 Cr | 47.65 | |
| Mar2024 | ₹634 Cr | 11.90 | |
| Mar2023 | ₹567 Cr | -23.73 | |
| Mar2022 | ₹743 Cr | - | |
Compare Contingent Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹118,078.6 Cr | -0.9% | 1.6% | -2.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹464,271.0 Cr | -0.5% | -0.3% | 18.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹226,843.0 Cr | 3.1% | 18.9% | 33.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹186,000.0 Cr | -1.5% | -1.6% | 35.6% | Stock Analytics | |
| MANKIND PHARMA | ₹100,137.0 Cr | -0.3% | -4.2% | -7.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,073.0 Cr | 2% | -3.8% | -0.7% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -0.9% |
1.6% |
-2.5% |
| SENSEX | -0.8% |
0.5% |
-3.8% |
You may also like the below Video Courses